OTC : BPTH

Bio-Path Holdings, Inc.

$0.03875 USD

$0.0 (10.71%)

Volume
3
Average Volume
32.68K
Market Capitalization
$362.01K
P/E Ratio
-0.05
Dividend Yield
0.00%
Price Target
Year High
$0.17
Year Low
$0.01
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$0.07

Industry, Sector & symbol

Stock Exchange OTC
CEO Vikram Paul Grover
Industry Biotechnology
Sector Healthcare
Current Symbol BPTH
CUSIP 09057N409
CIK 0001133818
Web https://www.biopathholdings.com
Phone 832 742 1357
Currency USD
Employees 1
Country US

Liquidity

Debt-to-Equity Ratio -0.06
Payout Ratio 0.00
Current Ratio 0.07
Quick Ratio 0.07
Cash Ratio 0.00

Sales & Book Value

Annual Sales -$
Price / Sales 0.00
Cash Flow -0.03
Price / Cash Flow -1.13
Price / Book -0.04

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 5 Analysts

Profitability

EPS (Most Recent Fiscal Year) -$1.1
Trailing P/E Ratio -0.05
PEG Ratio 0.00
P/E Growth 0.00
Net Income -$8.67M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity 76.46%
Return on Assets -899.85%

Financials Score

AltmanZ Score -304.49
Piotroski Score 1.00
Working Capital -8.47M
Total Assets 677K
Ebit -5.75M
Market Cap 373.69K
Total Liabilities 9.16M

Poll Results

About Bio-Path Holdings, Inc. (OTC:BPTH) Stock

Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is ... in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.

Frequently Asked Questions

What is the current Bio-Path Holdings, Inc. (BPTH) stock price?

Bio-Path Holdings, Inc.(OTC:BPTH) stock price is $0.03875 in the last trading session. During the trading session, BPTH stock reached the peak price of $0.17 while $0.01 was the lowest point it dropped to. The percentage change in BPTH stock occurred in the recent session was 10.71% while the dollar amount for the price change in BPTH stock was $0.0.

BPTH's industry and sector of operation?

The OTC listed BPTH is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BPTH?

Ana Tari Ashizawa | Senior Vice President of Research, Development & Clinical Design
Douglas Morris | Co-Founder, Director of Investor Relations & Secretary
Anthony Price | Senior Vice President of Finance, Accounting & Administration
Michael Hickey | Member of Scientific Advisory Board & VP of Clinical Operations
Vikram Paul Grover | President, Chief Executive Officer, Chief Financial Officer & Director

How many employees does BPTH have?

Number of BPTH employees currently stands at 1. BPTH operates from 4710 Bellaire Boulevard, Bellaire, TX 77401, US.

Link for BPTH official website?

Official Website of BPTH is: https://www.biopathholdings.com

How do I contact BPTH?

BPTH could be contacted at phone #832 742 1357 and can also be accessed through its website. BPTH operates from 4710 Bellaire Boulevard, Bellaire, TX 77401, US.

How many shares of BPTH are traded daily?

The average number of BPTH shares traded daily for last 3 months was 32.68K.

What is the market cap of BPTH currently?

The market value of BPTH currently stands at $362.01K with its latest stock price at $0.03875